<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3234">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01986101</url>
  </required_header>
  <id_info>
    <org_study_id>D1002001</org_study_id>
    <nct_id>NCT01986101</nct_id>
  </id_info>
  <brief_title>A Phase III Study of SM-13496 in Patients With Bipolar I Depression.</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of SM-13496 for the Treatment of Bipolar I Depression.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dainippon Sumitomo Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dainippon Sumitomo Pharma</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients
      with Bipolar I Depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to compare the efficacy of SM-13496 (20-60 or 80-120 mg/day)
      monotherapy with that of placebo in patients with depressive symptoms associated with
      bipolar I disorder by assessing the change from baseline in the MADRS total score at Week 6.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in  Montgomery-Asberg Depression Rating Scale (MADRS) total score</measure>
    <time_frame>Baseline, 1, 2, 3, 4, 5 and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the CGI-BP-S (depression) score.</measure>
    <time_frame>Baseline, 1, 2, 3, 4, 5 and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the SDS total score</measure>
    <time_frame>Baseline, 1, 2, 3, 4, 5 and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the YMRS total score</measure>
    <time_frame>Baseline, 1, 2, 3, 4, 5 and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the HAM-A total score</measure>
    <time_frame>Baseline, 1, 2, 3, 4, 5 and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse events (AEs) and Adverse drug reactions (ADRs)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">501</enrollment>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once daily orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SM-13496 20 -60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SM-13496 80-120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM-13496 (lurasidone HCl)</intervention_name>
    <description>SM-13496 20-60mg, SM-13496 80-120mg</description>
    <arm_group_label>SM-13496 20 -60 mg</arm_group_label>
    <arm_group_label>SM-13496 80-120 mg</arm_group_label>
    <other_name>Lurasidone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who were fully informed of and understand the objectives, procedures, and
             possible benefits and risks of the study and who provided written voluntary consent
             to participate in the study.

          -  Outpatients aged 18 through 74 years at the time of consent

          -  Patients meets DSM-IV-TR criteria for bipolar I disorder, most recent episode
             depressed (â‰¥ 4 weeks and less than 12 months) without psychotic features.

        Exclusion Criteria:

          -  Patients with imminent risk of suicide or injury to self, others, or property.

          -  Patients who had been hospitalized because of a manic or mixed episode within 60 days
             prior to screening.

          -  Patients who are otherwise considered ineligible for the study by the investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director, Drug Development Division</last_name>
    <role>Study Director</role>
    <affiliation>Dainippon Sumitomo Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dainippon Sumitomo Pharma Co., Ltd.</last_name>
    <email>cc@ds-pharma.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>China 5 sites</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Japan 60 sites</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Malaysia 4 sites</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philippines 5 sites</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Russia 7 sites</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taiwan 4 sites</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ukraine 7 sites</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 1, 2014</lastchanged_date>
  <firstreceived_date>November 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
